Novartis to Purchase Avidity Biosciences for $12 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 26 2025
0mins
Should l Buy RNA?
Source: WSJ
Acquisition Announcement: Novartis is acquiring Avidity Biosciences for $12 billion to enhance its focus on neuromuscular disorder treatments.
Company Background: Avidity Biosciences is a biotech firm based in San Diego.
Exclusion of Subsidiary: The acquisition does not include Avidity's subsidiary that is working on early-stage heart disease treatments.
Strategic Focus: This deal aligns with Novartis's long-term strategy to strengthen its portfolio in the neuromuscular disorder space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNA
Wall Street analysts forecast RNA stock price to rise
9 Analyst Rating
2 Buy
7 Hold
0 Sell
Hold
Current: 13.550
Low
72.00
Averages
75.63
High
96.00
Current: 13.550
Low
72.00
Averages
75.63
High
96.00
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atrium Therapeutics Launches as Independent Company Advancing Precision Cardiology
- Independent Launch: Atrium Therapeutics, Inc. officially launched today as an independent company focused on delivering RNA therapeutics for patients with rare genetic cardiomyopathies, starting with approximately $270 million in cash, marking a significant milestone in the precision cardiology sector.
- Clinical Trial Candidates: The company's lead candidates, ATR 1072 and ATR 1086, target PRKAG2 syndrome and PLN cardiomyopathy, respectively, and are expected to enter clinical trials, addressing the unmet medical needs for effective treatments for these severe conditions.
- Technological Platform Advantage: Atrium's RNA delivery platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides, aiming to directly target the biological drivers of cardiac diseases, thereby enhancing therapeutic efficacy and overcoming limitations of traditional delivery methods.
- Market Potential: With an estimated 1,000-2,000 patients suffering from PRKAG2 syndrome and 2,000-4,000 from PLN cardiomyopathy in the U.S., Atrium's innovative treatment solutions are poised to meet the urgent demand for effective therapies, potentially increasing the company's market share in precision cardiology.
See More
Atrium Therapeutics Launches as Independent Company Advancing Precision Cardiology
- Independent Launch: Atrium Therapeutics, Inc. officially launched today as an independent company focused on delivering RNA therapeutics for patients with rare genetic cardiomyopathies, starting with approximately $270 million in cash, marking a significant milestone in precision cardiology.
- Clinical Trial Candidates: The company's lead candidates, ATR 1072 and ATR 1086, target PRKAG2 syndrome and PLN cardiomyopathy respectively, with IND submissions expected in the second half of 2026, addressing a significant unmet need in the market with no approved therapies.
- Platform Advantage: Atrium's RNA delivery platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides, aiming to effectively target the biological drivers of cardiac diseases, thus paving the way for RNA therapies in precision cardiology with vast potential.
- Future Development Plans: Atrium plans to initiate IND-enabling preclinical studies for ATR 1086 in 2026, targeting an IND submission in 2027, and anticipates advancing both programs into clinical trials based on Phase 1 trial results, while expanding its precision cardiology pipeline.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Clinical Trial Results: Avidity Biosciences' del-desiran demonstrated efficacy in the Phase 1/2 MARINA trial for patients with myotonic dystrophy type 1, achieving approximately 40% mean reduction in DMPK mRNA, providing new hope for treatment.
- Multiple Improvement Metrics: The treatment showed significant improvements across various measures including muscle function, strength, mobility, and patient-reported outcomes, indicating that del-desiran could become a transformational therapy for patients, addressing the urgent need for effective treatments.
- Safety and Tolerability: The trial results indicated that del-desiran has an acceptable safety and tolerability profile, with most adverse events being mild or moderate, laying a solid foundation for its future clinical applications and boosting confidence among investors and patients.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR trial, with topline data expected in the second half of 2026, and if results are positive, it could become the first approved drug for DM1, representing significant market potential.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Significant Efficacy: Del-desiran effectively delivered siRNA to muscle, resulting in an approximately 40% mean reduction in DMPK mRNA across all treated participants, indicating the potential clinical value of this therapy for myotonic dystrophy type 1 (DM1).
- Functional Improvements: Participants exhibited significant improvements in multiple functional assessments post-treatment, including hand function, muscle strength, and activities of daily living, highlighting del-desiran's potential to enhance patient quality of life.
- Good Safety Profile: Most treatment-emergent adverse events were mild or moderate and did not lead to participant discontinuation, indicating that del-desiran has an acceptable safety and tolerability profile, which bolsters its credibility as a potential treatment option.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR study, which is expected to be the first approved drug for DM1, further validating the efficacy and safety of del-desiran.
See More
Avidity Biosciences Announces Share Distribution for Spin-Off
- Share Distribution Announcement: Avidity Biosciences has announced a share distribution on February 12, 2026, where holders of Avidity common stock will receive one share of Atrium Therapeutics for every ten shares held, aimed at enhancing company value through the spin-off.
- Merger Progress: This share distribution is linked to Avidity's acquisition by Novartis, with completion contingent on specific conditions including shareholder approval, indicating the company's strategic positioning in merger integration.
- Innovative Drug Platform: Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform is advancing clinical projects targeting rare muscle diseases, showcasing its innovative capabilities in RNA therapeutics, which could yield long-term growth potential for the company.
- Market Outlook: Through collaboration with Novartis, Avidity plans to expand its pipeline in cardiology and immunology, further enhancing its market competitiveness and addressing the growing healthcare demands.
See More
Atrium Therapeutics Launches as Independent Company Advancing Precision Cardiology
- Independent Launch: Atrium Therapeutics, Inc. officially launched today as an independent company focused on delivering RNA therapeutics for patients with rare genetic cardiomyopathies, starting with approximately $270 million in cash, marking a significant milestone in the precision cardiology sector.
- Clinical Trial Candidates: The company's lead candidates, ATR 1072 and ATR 1086, target PRKAG2 syndrome and PLN cardiomyopathy, respectively, and are expected to enter clinical trials, addressing the unmet medical needs for effective treatments for these severe conditions.
- Technological Platform Advantage: Atrium's RNA delivery platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides, aiming to directly target the biological drivers of cardiac diseases, thereby enhancing therapeutic efficacy and overcoming limitations of traditional delivery methods.
- Market Potential: With an estimated 1,000-2,000 patients suffering from PRKAG2 syndrome and 2,000-4,000 from PLN cardiomyopathy in the U.S., Atrium's innovative treatment solutions are poised to meet the urgent demand for effective therapies, potentially increasing the company's market share in precision cardiology.
See More
Atrium Therapeutics Launches as Independent Company Advancing Precision Cardiology
- Independent Launch: Atrium Therapeutics, Inc. officially launched today as an independent company focused on delivering RNA therapeutics for patients with rare genetic cardiomyopathies, starting with approximately $270 million in cash, marking a significant milestone in precision cardiology.
- Clinical Trial Candidates: The company's lead candidates, ATR 1072 and ATR 1086, target PRKAG2 syndrome and PLN cardiomyopathy respectively, with IND submissions expected in the second half of 2026, addressing a significant unmet need in the market with no approved therapies.
- Platform Advantage: Atrium's RNA delivery platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides, aiming to effectively target the biological drivers of cardiac diseases, thus paving the way for RNA therapies in precision cardiology with vast potential.
- Future Development Plans: Atrium plans to initiate IND-enabling preclinical studies for ATR 1086 in 2026, targeting an IND submission in 2027, and anticipates advancing both programs into clinical trials based on Phase 1 trial results, while expanding its precision cardiology pipeline.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Clinical Trial Results: Avidity Biosciences' del-desiran demonstrated efficacy in the Phase 1/2 MARINA trial for patients with myotonic dystrophy type 1, achieving approximately 40% mean reduction in DMPK mRNA, providing new hope for treatment.
- Multiple Improvement Metrics: The treatment showed significant improvements across various measures including muscle function, strength, mobility, and patient-reported outcomes, indicating that del-desiran could become a transformational therapy for patients, addressing the urgent need for effective treatments.
- Safety and Tolerability: The trial results indicated that del-desiran has an acceptable safety and tolerability profile, with most adverse events being mild or moderate, laying a solid foundation for its future clinical applications and boosting confidence among investors and patients.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR trial, with topline data expected in the second half of 2026, and if results are positive, it could become the first approved drug for DM1, representing significant market potential.
See More
Avidity Biosciences Reports Del-desiran Clinical Trial Results
- Significant Efficacy: Del-desiran effectively delivered siRNA to muscle, resulting in an approximately 40% mean reduction in DMPK mRNA across all treated participants, indicating the potential clinical value of this therapy for myotonic dystrophy type 1 (DM1).
- Functional Improvements: Participants exhibited significant improvements in multiple functional assessments post-treatment, including hand function, muscle strength, and activities of daily living, highlighting del-desiran's potential to enhance patient quality of life.
- Good Safety Profile: Most treatment-emergent adverse events were mild or moderate and did not lead to participant discontinuation, indicating that del-desiran has an acceptable safety and tolerability profile, which bolsters its credibility as a potential treatment option.
- Future Research Plans: Avidity is advancing the global Phase 3 HARBOR study, which is expected to be the first approved drug for DM1, further validating the efficacy and safety of del-desiran.
See More
Avidity Biosciences Announces Share Distribution for Spin-Off
- Share Distribution Announcement: Avidity Biosciences has announced a share distribution on February 12, 2026, where holders of Avidity common stock will receive one share of Atrium Therapeutics for every ten shares held, aimed at enhancing company value through the spin-off.
- Merger Progress: This share distribution is linked to Avidity's acquisition by Novartis, with completion contingent on specific conditions including shareholder approval, indicating the company's strategic positioning in merger integration.
- Innovative Drug Platform: Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform is advancing clinical projects targeting rare muscle diseases, showcasing its innovative capabilities in RNA therapeutics, which could yield long-term growth potential for the company.
- Market Outlook: Through collaboration with Novartis, Avidity plans to expand its pipeline in cardiology and immunology, further enhancing its market competitiveness and addressing the growing healthcare demands.
See More
